Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China
Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China
复制标题
DOI：
10.5582/bst.2020.03086
复制
发表时间：
2020-08-01
影响因子：
5.5
通讯作者：
Qian, Zhiping
中科院分区：
文献类型：
--
作者：
Zou, Ying;Guo, Hongying;Qian, Zhiping
为了解303例2019冠状病毒病（COVID-19）患者凝血功能的特点，我们评估了凝血功能与疾病状态的相关性。我们回顾性分析了303例确诊为COVID-19的患者，并评估了240例出院患者的临床资料。比较轻、重度两组患者的凝血功能。与轻度组相比，重度组中大多数患者为男性（76.9% vs. 49.8%）和老年人（中位年龄65 vs. 50），慢性基础疾病的比例更高（73.1% vs. 36.1%）。303例住院患者中有209例（69.0%）凝血参数异常。入院时两组凝血功能各项指标比较，重度组凝血指标异常的比例高于轻度组（100% vs. 66.1%）。重度组凝血参数中位数高于轻度组：国际标准化比值（1.04 vs. 1.01），凝血酶原时间（13.8 vs 13.4）秒，活化部分凝血活酶时间（43.2 vs 39.2）秒，纤维蛋白原（4.74 vs. 4.33）g/L，纤维蛋白原降解产物（2.61 vs.0.99）μ g/mL，D-二聚体（1.04 vs.0.43）μ g/mL，差异有统计学意义（p < 0.05）。COVID-19患者常见凝血功能障碍，尤其是纤维蛋白原和D-climer升高，升高的程度与疾病的严重程度有关。随着疾病的恢复，纤维蛋白原和活化部分凝血活酶时间也恢复正常。
To investigate the characteristic of coagulation function in 303 patients with Coronavirus disease 2019 (COVID-19), we evaluated the correlation between coagulation function and disease status. We retrospectively analyzed 303 patients diagnosed with COVID-19 and evaluated the clinical data of 240 patients who were discharged. The coagulation function of the two groups (mild and severe) was compared. Compared with the mild group, majority of patients in the severe group were male (76.9% vs. 49.8%) and elderly (median age 65 vs. 50), and the proportion with chronic underlying diseases was higher (73.1% vs. 36.1%). There were 209 abnormalities (69.0%) of coagulation parameters in 303 patients admitted to hospital. Comparison of various indexes of coagulation function between the two groups in admission, the proportion of abnormal coagulation indicators in the severe group was higher than that in the mild group (100% vs. 66.1%). The median coagulation parameters in the severe group were higher than those in the mild group: international normalized ratio (1.04 vs. 1.01), prothrombin time (13.8 vs. 13.4) seconds, activated partial thromboplastin time (43.2 vs. 39.2) seconds, fibrinogen (4.74 vs. 4.33) g/L, fibrinogen degradation products (2.61 vs. 0.99) mu g/mL, and D-dimer (1.04 vs. 0.43) mu g/mL, the differences were statistically significant (p < 0.05). Coagulation dysfunction is common in patients with COVID-19, especially fibrinogen and D-climer elevation, and the degree of elevation is related to the severity of the disease. As the disease recovers, fibrinogen and activated partial thromboplastin time also return to normal.